Developing Bacterial Consortia Therapeutics for Infectious and Inflammatory Disease Targets

Time: 10:30 am
day: Day One

Details:

• Providing an update on Seres’ clinical and pre-clinical pipeline
• Discussing candidates including SER-109, which in a Phase 3 Clinical Trial led to a statistically significant reduction in C.difficile recurrence

Speakers: